Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabay

Showing results (891-900 of 953) with videos related to

Pageof 96
Sort By:
Immunity|July 21, 2023
Targeted removal of macrophage-secreted interleukin-1 receptor antagonist protects against lethal Candida albicans sepsisHang Thi Thuy Gander-Bui, Joëlle Schläfli, Johanna Baumgartner, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 7, 2021
Excess Serum Interleukin-18 Distinguishes Patients With Pathogenic Mutations in PSTPIP1Deborah L Stone, Amanda Ombrello, Juan I Arostegui, et al.
Annals of the Rheumatic Diseases|October 6, 2011
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaborationKaterina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, et al.
Annals of the Rheumatic Diseases|February 24, 2018
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's diseaseCem Gabay, Bruno Fautrel, Jürgen Rech, et al.
NPJ Microgravity|May 27, 2026
Modeling the thermal behavior of photopolymers for in-space fabricationJonathan Ericson, Daniel Widerker, Eytan Stibbe, et al.
Annals of the Rheumatic Diseases|May 17, 2011
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registriesKaterina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, et al.
JHEP Reports : Innovation in Hepatology|January 2, 2026
Interleukin-18 binding protein deficiency results in gut microbiota dysbiosis and aggravated diet-induced MASH in miceEmmanuel Somm, Elodie Perroud, Yunju Jo, et al.
Blood|January 13, 2018
Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndromeEric S Weiss, Charlotte Girard-Guyonvarc'h, Dirk Holzinger, et al.
Annals of the Rheumatic Diseases|May 7, 2018
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaborationKim Lauper, Dan C Nordström, Karel Pavelka, et al.
Theranostics|July 21, 2020
Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast CancerAlison K Esser, Michael H Ross, Francesca Fontana, et al.
Pageof 96

Showing results (891-900 of 953) with videos related to

Sort By:
Pageof 96
Immunity|July 21, 2023
Targeted removal of macrophage-secreted interleukin-1 receptor antagonist protects against lethal Candida albicans sepsisHang Thi Thuy Gander-Bui, Joëlle Schläfli, Johanna Baumgartner, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 7, 2021
Excess Serum Interleukin-18 Distinguishes Patients With Pathogenic Mutations in PSTPIP1Deborah L Stone, Amanda Ombrello, Juan I Arostegui, et al.
Annals of the Rheumatic Diseases|October 6, 2011
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaborationKaterina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, et al.
Annals of the Rheumatic Diseases|February 24, 2018
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's diseaseCem Gabay, Bruno Fautrel, Jürgen Rech, et al.
NPJ Microgravity|May 27, 2026
Modeling the thermal behavior of photopolymers for in-space fabricationJonathan Ericson, Daniel Widerker, Eytan Stibbe, et al.
Annals of the Rheumatic Diseases|May 17, 2011
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registriesKaterina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, et al.
JHEP Reports : Innovation in Hepatology|January 2, 2026
Interleukin-18 binding protein deficiency results in gut microbiota dysbiosis and aggravated diet-induced MASH in miceEmmanuel Somm, Elodie Perroud, Yunju Jo, et al.
Blood|January 13, 2018
Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndromeEric S Weiss, Charlotte Girard-Guyonvarc'h, Dirk Holzinger, et al.
Annals of the Rheumatic Diseases|May 7, 2018
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaborationKim Lauper, Dan C Nordström, Karel Pavelka, et al.
Theranostics|July 21, 2020
Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast CancerAlison K Esser, Michael H Ross, Francesca Fontana, et al.
Pageof 96